GlobalData on MSN22h
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluationThe FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
Analyst Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $994.00. Discover top-rated stocks from highly ranked analysts ...
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...
1don MSN
We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...
The hottest area among healthcare investors right now revolves around advancements being made in weight loss. Known as ...
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback